vTv Therapeutics (NASDAQ:VTVT) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT) to a sell rating in a research note released on Saturday.

Several other research firms have also weighed in on VTVT. BTIG Research assumed coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $47.00 price objective (up previously from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, vTv Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $43.50.

vTv Therapeutics Stock Up 2.4%

VTVT stock opened at $37.91 on Friday. The stock has a market capitalization of $149.29 million, a price-to-earnings ratio of -11.42 and a beta of 0.50. The stock’s fifty day simple moving average is $28.68 and its 200-day simple moving average is $21.53. vTv Therapeutics has a 52-week low of $13.15 and a 52-week high of $38.46.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP grew its holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 148,314 shares of the biotechnology company’s stock after acquiring an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.